1. Market Research
  2. > Therapy Market Trends
  3. > Sodium-Glucose Co-Transporter 2 Inhibitor Industry
  4. > Sodium-Glucose Co-Transporter 2 Inhibitor Industry Statistics

Industries

Top countries

Publication dates

data types

Sodium-Glucose Co-Transporter 2 Inhibitor Industry Statistics

You might be interested in: Diabetes, Type 2 Diabetes, Cardiovascular Disease, Pharmaceutical, Endocrine Disease, Therapy, Antidiabetics, Insulin, Biguanide, Glucagon Like Peptide 1 Receptor Activator, Gliptins, Monoclonal Antibody, Hormone, Lipid Modifying Drug, Anti-Infective, Targeted Therapy, Analgesic, Opioid, Thiazolidinedione, Chemotherapy.

1-7 of 3 reports for Sodium-Glucose Co-Transpo...

Download Unlimited Documents from Trusted Public Sources

Sodium-Glucose Co-Transporter 2 Inhibitor Market in the US

  • September 2016
    21 pages
  • Sodium-Glucose ...  

    Antidiabetics  

  • United States  

View report >

Sodium-Glucose Co-Transporter 2 Inhibitor Market and Stroke Statistics in Europe

  • June 2016
    152 pages
  • Sodium-Glucose ...  

    Therapy  

    Antidiabetics  

View report >

Sodium-Glucose Co-Transporter 2 Inhibitor Market in the UK

  • January 2017
    10 pages
  • Sodium-Glucose ...  

    Antidiabetics  

  • United Kingdom  

    United States  

View report >

Sodium-Glucose Co-Transporter 2 Inhibitor Market in the US

  • February 2016
    23 pages
  • Sodium-Glucose ...  

    Antidiabetics  

  • United States  

View report >

Sodium-Glucose Co-Transporter 2 Inhibitor Market in the UK

  • August 2016
    21 pages
  • Sodium-Glucose ...  

    Antidiabetics  

    Gliptins  

  • United Kingdom  

View report >

Sodium-Glucose Co-Transporter 2 Inhibitor Market in the US - Forecast

  • December 2016
    16 pages
  • Sodium-Glucose ...  

    Antidiabetics  

  • United States  

View report >

Sodium-Glucose Co-Transporter 2 Inhibitor Market

  • August 2016
    48 pages
  • Sodium-Glucose ...  

    Antidiabetics  

    Therapy  

View report >


1 report for Sodium-Glucose Co-Transpo...

Purchase Reports From Reputable Market Research Publishers

Physician Views: How will US-based endocrinologists use Eli Lilly, Boehringer Ingelheim%s newly approved Glyxambi?

Physician Views: How will US-based endocrinologists use Eli Lilly, Boehringer Ingelheim%s newly approved Glyxambi?

  • € 685
  • Industry report
  • February 2015
  • by Firstword Pharma

Following a successful launch for the SGLT-2 inhibitor class – led by Johnson & Johnson's Invokana, which was approved by the FDA in March 2013 – the US diabetes market is poised to evolve furthe ...


Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.